RogerHideoKobayashiMDMS

PubMed

• 10 citations
  Dried Blood Spots, an Affordable Tool to Collect, Ship, and Sequence gDNA from Patients with an X-Linked Agammaglobulinemia Phenotype Residing in a Developing Country.
  Gesmar Rodrigues Silva Segundo, Anh Thi Van Nguyen, Huyen Thi Thanh Thuc, Le N. Q. Nguyen, Roger H. Kobayashi
  Frontiers in Immunology. 2018-02-16
• 1 citations
  Subcutaneous immunoglobulin 16.5% for the treatment of pediatric patients with primary antibody immunodeficiency.
  Sudhir Gupta, Roger H Kobayashi, Jiří Litzman, Laurel Cherwin, Sonja Hoeller
  Expert Review of Clinical Immunology. 2023-01-01
• 3 citations
  Immune globulin therapy and kidney disease: Overview and screening, monitoring, and management recommendations.
  Roger H Kobayashi, Michael T Rigas
  American Journal of Health-System Pharmacy. 2022-08-19

Journal Articles

• Vol.:(0123456789)1 3Journal of Clinical Immunology https://doi.org/10.1007/s10875-023-01509-4 ORIGINAL ARTICLE Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary...  
  Sudhir Gupta1 · James DeAngelo2 · Isaac Melamed3 · Jolan E. Walter4 · Ai‑Lan Kobayashi5 · Tracy Bridges 6 · J. Wesley Sublett 7 · Jonathan A. Bernstein8 · Alan Koterba..., Journal of Clinical Immunology, 5/9/2023
• Long-term Efficacy, Safety, and Tolerability of a Subcutaneous Immunoglobulin 16.5% (cutaquig®) in the Treatment of Patients with Primary Immunodeficiencies  
  Roger H Kobayashi, Jiří Litzman, Isaac Melamed, J Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, T Prescott Atkinson, Syed Rehman, Sonja Höller, et al., Clinical and Experimental Immunology Clinical and Experimental Immunology;, 10/8/2022
• Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome  
  Isaac Melamed, Roger H. Kobayashi, Maeve O'Connor, Ai Lan Kobayashi, Andrew Schechterman, Melinda Heffron, Sharon Canterberry, Holly Miranda, Nazia Rashid, Journal of Child and Adolescent Psychopharmacology, 2/18/2021
• Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies  
  Roger H. Kobayashi1*, Sudhir Gupta2, Isaac Melamed3, J. Fernando Mandujano4, Ai Lan Kobayashi5, Bruce Ritchie6, Bob Geng7, Thomas Prescott Atkinson8, Syed Rehm..., Front. Immunol., 04 February 2019, 2/3/2019
• Efficacy of human immunoglobulin 10% [Newgam] in Children with primary immunodeficiency diseases: subgroup analysis of a phase III multicenter, prospective, open label...  
  Ochs H, Melamed, Borte M, Moy J, Pyringer B, Kobayashi AD, Kobayashi RH, Knutsen, Immunotherapy. 2018, 8/8/2018
• Pharmacokinetics of a Novel High-Yield Human Intravenous Immunoglobulin 10% in Patients with Primary Immuno – deficiency Diseases; Analysis of a Phase III,Mu...  
  Melamed I, Borte M, Tranwnicek L, Moy J, Kobayashi A, Kobayashi RH, Ochs H, European J. Pharmaceutical Sci. 2018; 118:80 – 86, 6/15/2018
• Parvovirus B19-Induced Anemia as the Presenting Manifestation of X-Linked Hyper-IgM Syndrome  
  Seyama K, Kobayashi RH, Hasle H, Apter AJ, Rutledge JC, Rosen D, Ochs HD, Journal of Infectous Diseases, 8/1998
• Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses...  
  Richard L. Wasserman · William Lumry · James Harris · Robyn Levy · Roger Kobayashi, Journal of Clinical Immunology, 6/2016
• Immunoglobulin G4–related sclerosing disease of the paranasal sinus  
  Immunoglobulin G4–related sclerosing disease of the paranasal sinus Head & Neck Volum Robert H. Lindau, Yungpo Bernard Su, Roger Kobayashi and Russell B. Smith, Head and Neck, 10/2013
• Expert opinion regarding clinical and other outcome considerations in the formulatory review of immune globulin  
  Ricardo Sorensen, Chitra Dinakar, Ramsay Fuleihan, Sudhir Gupta, Alan Knutsen, Roger Kobayashi, Carol Lee Koski, Arnold I. Levinson, Ralph Shapiro, Richard L. Wasserman, Journal of Managed Care Pharmacy, 4/2007
• Octagam® 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases  
  Hans D. Ochs, Paul J. Pinciaro, Melvin Berger, Neil Kao, Jeffrey Kishiyama, Roger Kobayashi, William Shearer, Suzanne Skoda-Smith, William Smits, Mark Stein, Journal of Clinical Immunology, 5/2004
• Slow subcutaneous human intravenous immunoglobulin in the treatment of antibody immunodeficiency: Use of an old method with a new product  
  Stiehm ER, Casillas AM, Finkelstein JZ, Gallagher KT, Gromcy PM, Kobayashi RH, Oleske JM, Roberts RL, Sandberg ET, Wakim ME, Journal of Allergy and Clinical Immunology, 6/1998
• Join now to see all